123663-49-0

Basic information

• Product Name: Iguratimod
• Synonyms: IGURATIMOD;iguratimod( R&D);T 614;N-[7-methanesulfonamido-4-oxo-6-(phenoxy)chromen-3-yl]formamide;3-(Formylamino)-7-(methylsulfonylamino)-6-phenoxy-4H-1-benzopyran-4-one;N-[3-(Formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]methanesulfonamide;N-(7-(MethylsulfonaMido)-4-oxo-6-phenoxy-4H-chroMen-3-yl)forMaMide;IguratiMod (T 614)
• CAS NO: 123663-49-0
• Molecular Formula: C₁₇H₁₄N₂O₆S
• Molecular Weight: 374.37
• EINECS: 1308068-626-2
• Product Categories: API;Pharmaceutical intermediate;Pharmaceuticals
• Mol File: 123663-49-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 238.0 to 242.0 °C
• Boiling Point: 580.6 °C at 760 mmHg
• Flash Point: 304.9 °C
• Appearance: white powder
• Density: 1.52 g/cm³
• Vapor Pressure: 1.8E-13mmHg at 25°C
• Refractive Index: 1.673
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: DMSO (Slightly)
• PKA: 5.58±0.20(Predicted)
• CAS DataBase Reference: Iguratimod(CAS DataBase Reference)
• NIST Chemistry Reference: Iguratimod(123663-49-0)
• EPA Substance Registry System: Iguratimod(123663-49-0)

Safety Data

• Hazardous Substances Data: 123663-49-0(Hazardous Substances Data)

Usage

Description

In August 2011, China’s State FDA approved Simcere Pharmaceutical Group’s new drug application for iguratimod (T-614), a disease modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Preclinical in vivo studies indicated that iguratimod was effective in an established adjuvant-induced arthritis model (ED40=3.6 mg/kg) in rats and also efficacious in a type II collagen-induced arthritis model in DBA/1J mice at 30 mg and 100 mg/kg.

Originator

Toyama (Japan)

Uses

Iguratimod acts as an anti-inflammatory agent, used primarily in the treatment of rheumatoid arthritis.

Brand name

Iremod

Clinical Use

Iguratimod, which was discovered by Toyama Pharmaceuticals and jointly co-developed with Eisai in Japan, was approved by the PMDA (Pharmaceuticals and Medical Devices Agency) of Japan on June 29, 2012 for the treatment of rheumatoid arthritis. This drug was also independently developed by Simcere Pharmaceutical Group and is marked as Iremod? in China. The drug exhibited inhibitory effects on granuloma inflammation, and was shown to be efficacious for the prevention of joint destruction in adjuvant arthritis.

Synthesis

Several synthesis of iguratimod have been published, the most likely scale synthesis, which does not require chromatographic purification, is described in the scheme.The synthesis began with commercially available 3-nitro-4-chloro anisole (78) which was reacted with potassium phenoxide (generated from phenol and potassium t-butoxide at 110 oC) to provide the corresponding nitrophenyl ether which was subsequently reduced and sulfonylated to furnish sulfonamide 79. Next, this diphenyl ether was subjected to a Friedel-Crafts reaction with aminoacetonitrile hydrochloride which gave rise to aminomethylacetophenone 80 in 90% yield. This aminoketone was then formylated with formic trimethylacetic anhydride 81 at room temperature to afford formamide 82 in 91% yield, and this material was immediately subjected to O-demethylation conditions with aluminum trichloride and sodium iodide in acetonitrile to give the phenol 83 in 95% yield. Finally, treatment of the aminomethyl acetophenone phenol 83 with N,N-dimethylformamide dimethylacetal in DMF at low temperatures furnished iguratimod (XII) in 87% yield.

in vitro

iguratimod inhibited the release of immunoreactive il-1 beta from human monocytic cell line stimulated with lipopolysaccharides (lps) in a dose-dependent manner (0.3-30 μg/ml). northern blotting analysis using lps-stimulated thp-1 cells indicated that the inhibitory effect of iguratimod on il-1 beta production is caused by the suppression of il-1 beta mrna expression [1].

in vivo

administration of iguratimod did not inhibit the tumor growth, but resulted in attenuation of cachexia symptoms. furthermore, iguratimod decreased the serum levels of il-6, and also reduced its gene expression in the tumor tissues. in addition, exogenously administered il-6 nullified the suppressive effect of iguratimod [2].

IC 50

2.0 (hepatocyte-stimulating activities) and 6.6 μg/ml (immunoreactivities) for il-6 release.

references

[1] tanaka k, aikawa y, kawasaki h, asaoka k, inaba t, yoshida c. pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4h-1-benzopyran-4-one (t-614), a novel antiinflammatory agent. 4th communication: inhibitory effect on the production of interleukin-1 and interleukin-6. j pharmacobiodyn. 1992;15(11):649-55.[2] tanaka k, urata n, mikami m, ogasawara m, matsunaga t, terashima n, suzuki h. effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice. inflamm res. 2007;56(1):17-23.[3] hara m, abe t, sugawara s, mizushima y, hoshi k, irimajiri s, hashimoto h, yoshino s, matsui n, nobunaga m. long-term safety study of iguratimod in patients with rheumatoid arthritis. mod rheumatol. 2007;17(1):10-6.

InChI:InChI=1/C17H14N2O6S/c1-26(22,23)19-13-8-15-12(17(21)14(9-24-15)18-10-20)7-16(13)25-11-5-3-2-4-6-11/h2-10,19H,1H3,(H,18,20)

Synthetic route

N,N-dimethyl-formamide dimethyl acetal (4637-24-5) + α-formamido-2'-hydroxy-4'-methanesulfonamido-5'-phenoxyacetophenone (149457-03-4) → Iguratimod (123663-49-0)

Conditions	Yield
In N,N-dimethyl-formamide at 15℃; for 8h; Cyclization;	87%

Acetic formic anhydride (2258-42-6) + N-(3-amino-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl)methanesulfonamide (123663-48-9) → Iguratimod (123663-49-0)

Conditions	Yield
In dichloromethane at 20℃; for 1h; Formylation;	73%

N-(3-amino-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl)methanesulfonamide (123663-48-9) → Iguratimod (123663-49-0)

Conditions	Yield
With formic acid; acetic anhydride In dichloromethane; di-isopropyl ether	73%

4-methoxy-2-nitro-1-phenoxybenzene (84594-95-6) → Iguratimod (123663-49-0)

Conditions	Yield
Multi-step reaction with 6 steps 1: 72 percent / 4N aq. HCl; Fe / ethanol / 0.33 h / 65 - 70 °C 2: 82 percent / pyridine / 1 h / 20 °C 3: 90 percent / AlCl3; HCl / nitrobenzene / 10 h / 25 - 30 °C 4: 91 percent / acetone / 3 h 5: 95 percent / NaI; AlCl3 / acetonitrile / 3 h / 20 °C 6: 87 percent / dimethylformamide / 8 h / 15 °C View Scheme
Multi-step reaction with 9 steps 1: 72 percent / 4N aq. HCl; Fe / ethanol / 0.33 h / 65 - 70 °C 2: 82 percent / pyridine / 1 h / 20 °C 3: 84 percent / aluminum chloride / CH2Cl2 / 1 h / 15 - 20 °C 4: 70 percent aq. HClO4 / 1 h / 20 °C 5: H2O / 0.08 h / Heating 6: H2 / 5 percent Pd/C / acetic acid / 1 h / 40 - 45 °C / 760 Torr 7: 97 percent / Br2 / CHCl3 / 0.5 h / 25 - 30 °C 8: 80 percent / NaN3; DMF / 1 h / 70 - 75 °C 9: 73 percent / CH2Cl2 / 1 h / 20 °C View Scheme

5-methoxy-2-phenoxyaniline (76838-72-7) → Iguratimod (123663-49-0)

Conditions	Yield
Multi-step reaction with 5 steps 1: 82 percent / pyridine / 1 h / 20 °C 2: 90 percent / AlCl3; HCl / nitrobenzene / 10 h / 25 - 30 °C 3: 91 percent / acetone / 3 h 4: 95 percent / NaI; AlCl3 / acetonitrile / 3 h / 20 °C 5: 87 percent / dimethylformamide / 8 h / 15 °C View Scheme
Multi-step reaction with 8 steps 1: 82 percent / pyridine / 1 h / 20 °C 2: 84 percent / aluminum chloride / CH2Cl2 / 1 h / 15 - 20 °C 3: 70 percent aq. HClO4 / 1 h / 20 °C 4: H2O / 0.08 h / Heating 5: H2 / 5 percent Pd/C / acetic acid / 1 h / 40 - 45 °C / 760 Torr 6: 97 percent / Br2 / CHCl3 / 0.5 h / 25 - 30 °C 7: 80 percent / NaN3; DMF / 1 h / 70 - 75 °C 8: 73 percent / CH2Cl2 / 1 h / 20 °C View Scheme

2-chloro-5-methoxynitrobenzene (10298-80-3) → Iguratimod (123663-49-0)

Conditions	Yield
Multi-step reaction with 7 steps 1: 84 percent / potassium tert-butoxide / dimethylformamide / 4 h / 110 °C 2: 72 percent / 4N aq. HCl; Fe / ethanol / 0.33 h / 65 - 70 °C 3: 82 percent / pyridine / 1 h / 20 °C 4: 90 percent / AlCl3; HCl / nitrobenzene / 10 h / 25 - 30 °C 5: 91 percent / acetone / 3 h 6: 95 percent / NaI; AlCl3 / acetonitrile / 3 h / 20 °C 7: 87 percent / dimethylformamide / 8 h / 15 °C View Scheme
Multi-step reaction with 10 steps 1: 84 percent / potassium tert-butoxide / dimethylformamide / 4 h / 110 °C 2: 72 percent / 4N aq. HCl; Fe / ethanol / 0.33 h / 65 - 70 °C 3: 82 percent / pyridine / 1 h / 20 °C 4: 84 percent / aluminum chloride / CH2Cl2 / 1 h / 15 - 20 °C 5: 70 percent aq. HClO4 / 1 h / 20 °C 6: H2O / 0.08 h / Heating 7: H2 / 5 percent Pd/C / acetic acid / 1 h / 40 - 45 °C / 760 Torr 8: 97 percent / Br2 / CHCl3 / 0.5 h / 25 - 30 °C 9: 80 percent / NaN3; DMF / 1 h / 70 - 75 °C 10: 73 percent / CH2Cl2 / 1 h / 20 °C View Scheme

N-(5-methoxy-2-phenoxyphenyl)methanesulfonamide (123664-84-6) → Iguratimod (123663-49-0)

Conditions	Yield
Multi-step reaction with 4 steps 1: 90 percent / AlCl3; HCl / nitrobenzene / 10 h / 25 - 30 °C 2: 91 percent / acetone / 3 h 3: 95 percent / NaI; AlCl3 / acetonitrile / 3 h / 20 °C 4: 87 percent / dimethylformamide / 8 h / 15 °C View Scheme
Multi-step reaction with 7 steps 1: 84 percent / aluminum chloride / CH2Cl2 / 1 h / 15 - 20 °C 2: 70 percent aq. HClO4 / 1 h / 20 °C 3: H2O / 0.08 h / Heating 4: H2 / 5 percent Pd/C / acetic acid / 1 h / 40 - 45 °C / 760 Torr 5: 97 percent / Br2 / CHCl3 / 0.5 h / 25 - 30 °C 6: 80 percent / NaN3; DMF / 1 h / 70 - 75 °C 7: 73 percent / CH2Cl2 / 1 h / 20 °C View Scheme

methyl 2-hydroxy-4-methylsulfonylamino-5-phenoxyphenyl ketone (123664-52-8) → Iguratimod (123663-49-0)

Conditions	Yield
Multi-step reaction with 6 steps 1: 70 percent aq. HClO4 / 1 h / 20 °C 2: H2O / 0.08 h / Heating 3: H2 / 5 percent Pd/C / acetic acid / 1 h / 40 - 45 °C / 760 Torr 4: 97 percent / Br2 / CHCl3 / 0.5 h / 25 - 30 °C 5: 80 percent / NaN3; DMF / 1 h / 70 - 75 °C 6: 73 percent / CH2Cl2 / 1 h / 20 °C View Scheme

7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (123662-55-5) → Iguratimod (123663-49-0)

Conditions	Yield
Multi-step reaction with 4 steps 1: H2 / 5 percent Pd/C / acetic acid / 1 h / 40 - 45 °C / 760 Torr 2: 97 percent / Br2 / CHCl3 / 0.5 h / 25 - 30 °C 3: 80 percent / NaN3; DMF / 1 h / 70 - 75 °C 4: 73 percent / CH2Cl2 / 1 h / 20 °C View Scheme

N-(4-oxo-6-phenoxy-2,3-dihydro-4H-7-chromenyl)methanesulfonamide (123664-21-1) → Iguratimod (123663-49-0)

Conditions	Yield
Multi-step reaction with 3 steps 1: 97 percent / Br2 / CHCl3 / 0.5 h / 25 - 30 °C 2: 80 percent / NaN3; DMF / 1 h / 70 - 75 °C 3: 73 percent / CH2Cl2 / 1 h / 20 °C View Scheme

3-bromo-2,3-dihydro-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (123664-34-6) → Iguratimod (123663-49-0)

Conditions	Yield
Multi-step reaction with 2 steps 1: 80 percent / NaN3; DMF / 1 h / 70 - 75 °C 2: 73 percent / CH2Cl2 / 1 h / 20 °C View Scheme

N-(2-(2-methoxy-4-(methylsulfonamido)-5-phenoxyphenyl)-2-oxoethyl)formamide (149456-98-4) → Iguratimod (123663-49-0)

Conditions	Yield
Multi-step reaction with 2 steps 1: 95 percent / NaI; AlCl3 / acetonitrile / 3 h / 20 °C 2: 87 percent / dimethylformamide / 8 h / 15 °C View Scheme

α-amino-2-methoxy-4-methanesulfonamido-5-phenoxyacetophenone hydrochloride → Iguratimod (123663-49-0)

Conditions	Yield
Multi-step reaction with 3 steps 1: 91 percent / acetone / 3 h 2: 95 percent / NaI; AlCl3 / acetonitrile / 3 h / 20 °C 3: 87 percent / dimethylformamide / 8 h / 15 °C View Scheme

4-ethoxy-7-methanesulfonylamino-6-phenoxy-chromenylium; perchlorate → Iguratimod (123663-49-0)

Conditions	Yield
Multi-step reaction with 5 steps 1: H2O / 0.08 h / Heating 2: H2 / 5 percent Pd/C / acetic acid / 1 h / 40 - 45 °C / 760 Torr 3: 97 percent / Br2 / CHCl3 / 0.5 h / 25 - 30 °C 4: 80 percent / NaN3; DMF / 1 h / 70 - 75 °C 5: 73 percent / CH2Cl2 / 1 h / 20 °C View Scheme

phenol (108-95-2) + pentacarbonyl(3-cyclohex-1-enyl-1-ethoxy-2-propyn-1-ylidene)tungsten → Iguratimod (123663-49-0)

Conditions	Yield
Multi-step reaction with 7 steps 1: 84 percent / potassium tert-butoxide / dimethylformamide / 4 h / 110 °C 2: 72 percent / 4N aq. HCl; Fe / ethanol / 0.33 h / 65 - 70 °C 3: 82 percent / pyridine / 1 h / 20 °C 4: 90 percent / AlCl3; HCl / nitrobenzene / 10 h / 25 - 30 °C 5: 91 percent / acetone / 3 h 6: 95 percent / NaI; AlCl3 / acetonitrile / 3 h / 20 °C 7: 87 percent / dimethylformamide / 8 h / 15 °C View Scheme
Multi-step reaction with 10 steps 1: 84 percent / potassium tert-butoxide / dimethylformamide / 4 h / 110 °C 2: 72 percent / 4N aq. HCl; Fe / ethanol / 0.33 h / 65 - 70 °C 3: 82 percent / pyridine / 1 h / 20 °C 4: 84 percent / aluminum chloride / CH2Cl2 / 1 h / 15 - 20 °C 5: 70 percent aq. HClO4 / 1 h / 20 °C 6: H2O / 0.08 h / Heating 7: H2 / 5 percent Pd/C / acetic acid / 1 h / 40 - 45 °C / 760 Torr 8: 97 percent / Br2 / CHCl3 / 0.5 h / 25 - 30 °C 9: 80 percent / NaN3; DMF / 1 h / 70 - 75 °C 10: 73 percent / CH2Cl2 / 1 h / 20 °C View Scheme

N-[3-(formylamino)-4-oxo-6-phenoxy-4H-chromen-7-yl]methanesulfonamide monohydrate (761454-93-7) → Iguratimod (123663-49-0)

Conditions	Yield
at 160℃; for 1h; Product distribution / selectivity;
In acetonitrile at 25℃; for 24h; Product distribution / selectivity;

Iguratimod (123663-49-0) + methyl iodide (74-88-4) → 3-(N-formyl-N-methyl)amino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one

Conditions	Yield
In diethyl ether; water; N,N-dimethyl-formamide	75%

Iguratimod (123663-49-0) → N-[3-(formylamino)-4-oxo-6-phenoxy-4H-chromen-7-yl]methanesulfonamide monohydrate (761454-93-7)

Conditions	Yield
With water at 25℃; for 168h; Product distribution / selectivity;
With water at 25℃; for 24h; Product distribution / selectivity;

Upstream product

• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 149457-03-4 α-formamido-2'-hydroxy-4'-methanesulfonamido-5'-phenoxyacetophenone 
• 123663-48-9 N-(3-amino-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl)methanesulfonamide 
• 761454-93-7 N-[3-(formylamino)-4-oxo-6-phenoxy-4H-chromen-7-yl]methanesulfonamide monohydrate 
• 108-95-2 phenol 
• 149436-41-9 α-amino-2-methoxy-4-methanesulfonamido-5-phenoxyacetophenone hydrochloride 
• 149456-98-4 N-(2-(2-methoxy-4-(methylsulfonamido)-5-phenoxyphenyl)-2-oxoethyl)formamide 
• 123664-34-6 3-bromo-2,3-dihydro-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one 
• 123664-21-1 N-(4-oxo-6-phenoxy-2,3-dihydro-4H-7-chromenyl)methanesulfonamide 
• 123662-55-5 7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one 
• 123664-52-8 methyl 2-hydroxy-4-methylsulfonylamino-5-phenoxyphenyl ketone 
• 123664-84-6 N-(5-methoxy-2-phenoxyphenyl)methanesulfonamide 
• 10298-80-3 2-chloro-5-methoxynitrobenzene 
• 76838-72-7 5-methoxy-2-phenoxyaniline 

Downstream Products

• 761454-93-7 N-[3-(formylamino)-4-oxo-6-phenoxy-4H-chromen-7-yl]methanesulfonamide monohydrate 

Related news

Iguratimod (cas 123663-49-0) (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways08/08/2019

IntroductionIguratimod (T-614) has been confirmed as a highly efficacious and safe novel disease-modifying anti-rheumatic drug (DMARD) for rheumatoid arthritis therapy in China and Japan due to its potent anti-inflammation effect. Here, we investigate the effects of Iguratimod on osteoclast diff...detailed

Iguratimod (cas 123663-49-0) ameliorates inflammatory responses by modulating the Th17/Treg paradigm in dextran sulphate sodium-induced murine colitis08/07/2019

Inflammatory bowel disease (IBD) is an autoimmune disease with an abnormal and persistent immune response. Iguratimod, a novel anti-rheumatic drug, exhibits anti-inflammatory effects and regulates immune response. The role of iguratimod in intestinal mucosal inflammation and immunity has not bee...detailed

Relevant articles and documents

NOVEL CRYSTAL OF N- 3-(FORMYLAMINO)-4-OXO-6-PHENOXY-4H-CROME NE-7-YL METHANESULFONAMIDE

The crystal of N-[3-(formylamino)-4-oxo-6-phenoxy-4H-chromen-7-yl]methanesulfonamide having peaks at the positions of 6.00±0.05°, 10.54±0.05°, 17.42±0.08°, 18.39±0.08°, 20.13±0.10° and 23.01±0.10° on 2θ of diffraction angle in powder X-ray diffraction pattern of present invention is low hygroscopic, stable under a high humidity condition, and is useful as a drug substance of excellent anti-inflammatory agent.

Antiangiogenic combination therapy for the treatment of cancer

The present invention provides combinations of a DNA topoisomerase I inhibiting agent and a selective COX-2 inhibiting agent for preventing, treating, and/or reducing the risk of developing a neoplasia disorder in a mammal.

4H-1-benzopyran-4-one derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient

This invention relates to a 4H-1-benzopyran-4-one derivative represented by the formula: STR1 or a salt thereof, a process for producing the same and a pharmaceutical composition comprising the same as active ingredient.